Focused On-demand Library for Coagulation factor IX

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
P00740

UPID:
FA9_HUMAN

ALTERNATIVE NAMES:
Christmas factor; Plasma thromboplastin component

ALTERNATIVE UPACC:
P00740; A8K9N4; F2RM36; Q5FBE1; Q5JYJ8

BACKGROUND:
The protein Coagulation factor IX, known alternatively as Christmas factor or Plasma thromboplastin component, is essential in the blood coagulation process. It functions by converting factor X to its active form, in collaboration with Ca(2+) ions, phospholipids, and factor VIIIa, underscoring its role in the intrinsic coagulation pathway.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Coagulation factor IX could open doors to potential therapeutic strategies for treating Hemophilia B, Thrombophilia due to factor IX defect, and Warfarin sensitivity. These conditions underscore the protein's importance in blood coagulation and therapeutic drug responses.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 148 of 8789